ArticleMolecular genetics and genomics : MGG2025
Complete genome analysis of Bacillus velezensis HF-14,109 with potential for broad-spectrum antimicrobial activity and high enzyme-producing ability from common carp (Cyprinus carpio L.).
Article in Molecular genetics and genomics : MGG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Research Progress on the Effect ofCurrent issues in molecular biology · 2026Review
- Genomic and Phenotypic Characterization of the Probiotic Potential and Safety of Bacillus velezensis CH3-2 Isolated from Chahua Chicken.Probiotics and antimicrobial proteins · 2026Article
- Fish-Derived Clostridium butyricum LZK-08: Genomic Insights and Probiotic Evaluation in Largemouth Bass.Probiotics and antimicrobial proteins · 2026Article
- Genetic and biotechnological potential of thermophilic Streptomyces sp. isolated from Baikal freshwater psychrophilic sponge.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bacillus velezensis (B. velezensis) HF-14,109 is an aerobic Gram-positive bacterium isolated from the gut of healthy carp (Cyprinus carpio L.). Here, we sequenced and annotated the genome of HF-14,109, identified and classified its enzyme-producing genes and secondary metabolite biosynthesis gene clusters (BGCs), and verified the inhibitory effects on pathogenic bacteria in vitro. Results suggested that HF-14,109 had a circular 4,214,172 bp genome that contains 4,392 predicted genes with an average length and GC content of 851.56 bp and 46.94%, respectively. A total of 210 non-coding RNAs, 8 CRISPR sequences, and 152 tandem repeats were predicted. Based on a CAZy database analysis, HF-14,109 contains 93 genes encoding enzymes for carbohydrate-related processes, 38 of which were glycoside hydrolase genes and divided into 20 families. Based on enzyme predictions, HF-14,109 had the capability to hydrolyze high molecular carbohydrates such as starch, disaccharides such as lactose and sucrose, and non-starch polysaccharides such as β-glucan, mannan, fructan and xylan. Twelve BGCs for producting secondary metabolites were identified by antiSMASH analysis, 5 of which were predicted to encode polyketide synthases (PKSs) and non-ribosomal peptide synthetases (NRPSs), indicating that HF-14,109 could produce multiple secondary metabolites. The genome of HF-14,109 contained numerous genes encoding glycoside hydrolases and BGCs for producting secondary metabolites. Besides, the HF-14,109 could inhibit pathogenic bacteria such as E. tarda, A. hydrophila, S. aurenus, and E. coli in vitro. In conclusion, our results demonstrate that HF-14,109 has the effects of hydrolyzing non-starch polysaccharides and inhibiting pathogenic bacteria, which lays a solid foundation for elucidating its antibacterial and enzyme-producing mechanisms, and is expected to be developed as a probiotic for aquaculture feed in the future.
Indexed as
Identifiers
40011251What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.